Ozone-high-doses ACC. to Dr. Lahodny and the latest scientific results.

J. Lahodny
{"title":"Ozone-high-doses ACC. to Dr. Lahodny and the latest scientific results.","authors":"J. Lahodny","doi":"10.7203/jo3t.6.7.2022.25984","DOIUrl":null,"url":null,"abstract":"Self-funding his own work on the so-called therapeutic effects of medical ozone with respect to its alleged potential impacts on mitochondria and stem cells, he has been focusing since 2010 on an innovative form of ozone therapy called OHT—“Ozonhochdosistherapie”— commonly known as “10 pass” in the USA. Through a specific process involving 10 repeated interactive transits incurred via autohemotherapy, the blood is “fused” with 200 ml of ozone gas respectively brought to a concentration of 70 mcg/ml, thus providing a cumulative ozone intake of 140,000 mcg. \nThe evolution of the ozonotherapeutic treatment promoted by Lahodny would then consist, in a way, in breaking the restrictive rules relating to pragmatic dosage which tended to prevail until now with regard to a usual protocol which still remains well anchored in traditional customs and habits. Indeed, any former procedure usually involved a single injection of ozonated autologous blood therapy containing 200 ml of ozone at a concentration of 40 mcg, after which the session would end. This conceptual limit was based on an arbitrary credo that exceeding \nthis dose boundary—in terms of both quantity and concentration administered—would be likely to result in cell bursting by blood dissolution, a supputive risk whose consequences had previously been considered hypothetically lethal. \nIn 2014, he discovered and refined a new dosage—L1—that he believes would activate the growth of stem cells and the production of adenosine triphosphate (ATP). Its application can be summed up as a major autologous blood therapy combined with massive doses of ozone injections both in terms of concentration — up to 70 mcg/ml in ozon IV or even 80 mcg/ml in rectal insufflation - and quantity: which generally implied 140,000 mcg, but sometimes up to 280,000 mcg in the treatment of more complex conditions. Thanks to this innovative approach, Lahodny claimed to obtain therapeutic results that he described as “exceptional” in the treatment of a number of chronic pathologies as well as several other morbid conditions which are generally considered difficult to treat.","PeriodicalId":137241,"journal":{"name":"Journal of Ozone Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ozone Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7203/jo3t.6.7.2022.25984","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Self-funding his own work on the so-called therapeutic effects of medical ozone with respect to its alleged potential impacts on mitochondria and stem cells, he has been focusing since 2010 on an innovative form of ozone therapy called OHT—“Ozonhochdosistherapie”— commonly known as “10 pass” in the USA. Through a specific process involving 10 repeated interactive transits incurred via autohemotherapy, the blood is “fused” with 200 ml of ozone gas respectively brought to a concentration of 70 mcg/ml, thus providing a cumulative ozone intake of 140,000 mcg. The evolution of the ozonotherapeutic treatment promoted by Lahodny would then consist, in a way, in breaking the restrictive rules relating to pragmatic dosage which tended to prevail until now with regard to a usual protocol which still remains well anchored in traditional customs and habits. Indeed, any former procedure usually involved a single injection of ozonated autologous blood therapy containing 200 ml of ozone at a concentration of 40 mcg, after which the session would end. This conceptual limit was based on an arbitrary credo that exceeding this dose boundary—in terms of both quantity and concentration administered—would be likely to result in cell bursting by blood dissolution, a supputive risk whose consequences had previously been considered hypothetically lethal. In 2014, he discovered and refined a new dosage—L1—that he believes would activate the growth of stem cells and the production of adenosine triphosphate (ATP). Its application can be summed up as a major autologous blood therapy combined with massive doses of ozone injections both in terms of concentration — up to 70 mcg/ml in ozon IV or even 80 mcg/ml in rectal insufflation - and quantity: which generally implied 140,000 mcg, but sometimes up to 280,000 mcg in the treatment of more complex conditions. Thanks to this innovative approach, Lahodny claimed to obtain therapeutic results that he described as “exceptional” in the treatment of a number of chronic pathologies as well as several other morbid conditions which are generally considered difficult to treat.
Ozone-high-doses ACC。拉霍尼博士和最新的科学成果
自2010年以来,他一直专注于一种名为OHT (Ozonhochdosistherapie)的创新臭氧疗法,这种疗法在美国通常被称为“10 pass”,他自己出资研究所谓的医用臭氧治疗效果,即所谓的对线粒体和干细胞的潜在影响。通过一个特定的过程,包括通过自体血液疗法进行的10次重复相互作用过境,血液分别与200毫升浓度为70微克/毫升的臭氧气体“融合”,从而提供累计14万微克的臭氧摄入量。因此,Lahodny提倡的臭氧治疗的发展在某种程度上包括打破与实用剂量有关的限制性规则,这些规则到目前为止在一种仍然牢固地扎根于传统习俗和习惯的常规方案中往往占主导地位。事实上,任何先前的治疗方法通常都是单次注射含有200毫升浓度为40微克臭氧的臭氧自体血液疗法,之后治疗就结束了。这个概念上的限制是基于一种武断的信条,即超过这个剂量界限——无论是剂量还是浓度——都可能导致细胞因血液溶解而破裂,这是一种假定的风险,其后果以前被认为是致命的。2014年,他发现并改进了一种新的剂量——l1,他认为这种剂量可以激活干细胞的生长和三磷酸腺苷(ATP)的产生。它的应用可以概括为一种主要的自体血液疗法,结合大剂量的臭氧注射,无论是浓度——臭氧IV高达70微克/毫升,直肠注入甚至80微克/毫升——还是数量:通常意味着14万微克,但有时在治疗更复杂的疾病时高达28万微克。由于这种创新的方法,Lahodny声称在治疗许多慢性疾病以及其他一些通常被认为难以治疗的病态疾病方面获得了他称之为“特殊”的治疗结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信